Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT.

Cancer Discov. 2018 Apr 12. pii: CD-17-1256. doi: 10.1158/2159-8290.CD-17-1256. [Epub ahead of print]

PMID:
29650534
2.

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, Shaw AT, Mehan WA, Shih HA, Gainor JF.

J Thorac Oncol. 2018 Apr;13(4):550-558. doi: 10.1016/j.jtho.2018.01.012. Epub 2018 Jan 31.

PMID:
29378267
3.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23.

4.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

5.

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.

Hwang WL, Niemierko A, Hwang KL, Hubbeling H, Schapira E, Gainor JF, Keane FK.

JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808. No abstract available.

PMID:
28973343
6.

Regulatory T cells occupy an isolated niche in the intestine that is antigen independent.

Korn LL, Hubbeling HG, Porrett PM, Yang Q, Barnett LG, Laufer TM.

Cell Rep. 2014 Dec 11;9(5):1567-1573. doi: 10.1016/j.celrep.2014.11.006. Epub 2014 Dec 4.

7.

Conventional CD4+ T cells regulate IL-22-producing intestinal innate lymphoid cells.

Korn LL, Thomas HL, Hubbeling HG, Spencer SP, Sinha R, Simkins HM, Salzman NH, Bushman FD, Laufer TM.

Mucosal Immunol. 2014 Sep;7(5):1045-57. doi: 10.1038/mi.2013.121. Epub 2014 Jan 22.

8.

Myelofibrosis 2012: it's complicated.

Hubbeling HG, Frank DM, Hexner EO.

Ther Adv Hematol. 2012 Jun;3(3):131-46. doi: 10.1177/2040620712437754.

9.

NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis.

Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, Zaugg C, Pei H, Geissmann F, Ley K, Hedrick CC.

Circ Res. 2012 Feb 3;110(3):416-27. doi: 10.1161/CIRCRESAHA.111.253377. Epub 2011 Dec 22.

10.

The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes.

Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, Geissmann F, Hedrick CC.

Nat Immunol. 2011 Jul 3;12(8):778-85. doi: 10.1038/ni.2063.

Supplemental Content

Loading ...
Support Center